Search - tctmd.com

Displaying 21 - 34 of 34

Sort: Relevancy | Date

Presentation TCT 2022

TCT 212: Twenty-Four Month Results in Patients with Resistant Hypertension After Endovascular Ultrasound Renal Denervation in the RADIANCE-HTN TRIO Trial

Presenter: Roland Schmieder

September 17, 2022

Presentation

TCT 211: Home Blood Pressure Response to Ultrasound Renal Denervation - a Patient-level Pooled Analysis of the RADIANCE-HTN SOLO and TRIO Randomised, Sham-controlled Trials

Presenter: Andrew Sharp

September 17, 2022

Presentation TCT 2022

TCT 213: Impact of Cardiac Neuromodulation Therapy (CNT) on Systolic Blood Pressure and Pulse Pressure in Hypertensive Patients Indicated for a Pacemaker: Results of a Crossover Study

Presenter: Daniel Burkhoff

September 17, 2022

Presentation TCT 2022

TCT 210: Long-term blood pressure results after renal sympathetic denervation using endovascular ultrasound

Presenter: Karl Fengler

September 17, 2022

News Conference News TCT 2022

New Faces, New Formats, New Tech: What to Expect From TCT 2022

Shelley Wood

September 07, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2022

Todd Neale

August 01, 2022

News Daily News

RADIANCE II Top-Line Results Promising for Ultrasound Renal Denervation

Todd Neale

July 26, 2022

Presentation EuroPCR 2022

Blood pressure and MACE reductions after renal denervation: 3-year GSR results

Presenter: Felix Mahfoud

May 20, 2022

News Conference News EuroPCR 2022

Registry Data Hint at MACE Benefit With Renal Denervation

Michael O'Riordan

May 17, 2022

News Opinion Editor's Corner EuroPCR 2022

EuroPCR Kicks Off In Person Next Week in Paris: Here’s What to Expect

Shelley Wood

May 12, 2022

Presentation ARCH 2022

Current Status and Future of Renal Denervation for Hypertension

Presenter: Tim A. Fischell

April 23, 2022

News Conference News ACC 2022

SPYRAL HTN-ON MED at 3 Years: Renal Denervation’s BP Impact Endures

Todd Neale

April 08, 2022

Presentation ACC 2022

Long Term Efficacy and Safety of Renal Denervation on Blood Pressure in Patients on Antihypertension Medications: 3-Year Outcomes from the SPYRAL HTN-ON MED Trial

Presenter: Felix Mahfoud

April 04, 2022

News Conference News ACC 2022

What’s Going to Be Hot at ACC 2022, In Person or Virtual

Shelley Wood

March 28, 2022

Advertisement

TCT 212: Twenty-Four Month Results in Patients with Resistant Hypertension After Endovascular Ultrasound Renal Denervation in the RADIANCE-HTN TRIO Trial

TCT 211: Home Blood Pressure Response to Ultrasound Renal Denervation - a Patient-level Pooled Analysis of the RADIANCE-HTN SOLO and TRIO Randomised, Sham-controlled Trials

TCT 213: Impact of Cardiac Neuromodulation Therapy (CNT) on Systolic Blood Pressure and Pulse Pressure in Hypertensive Patients Indicated for a Pacemaker: Results of a Crossover Study

TCT 210: Long-term blood pressure results after renal sympathetic denervation using endovascular ultrasound

New Faces, New Formats, New Tech: What to Expect From TCT 2022

TCTMD’s Top 10 Most Popular Stories for July 2022

RADIANCE II Top-Line Results Promising for Ultrasound Renal Denervation

Blood pressure and MACE reductions after renal denervation: 3-year GSR results

Registry Data Hint at MACE Benefit With Renal Denervation

EuroPCR Kicks Off In Person Next Week in Paris: Here’s What to Expect

Current Status and Future of Renal Denervation for Hypertension

SPYRAL HTN-ON MED at 3 Years: Renal Denervation’s BP Impact Endures

Long Term Efficacy and Safety of Renal Denervation on Blood Pressure in Patients on Antihypertension Medications: 3-Year Outcomes from the SPYRAL HTN-ON MED Trial

What’s Going to Be Hot at ACC 2022, In Person or Virtual

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content